Page last updated: 2024-09-05

campesterol and pyrroles

campesterol has been researched along with pyrroles in 9 studies

Compound Research Comparison

Studies
(campesterol)
Trials
(campesterol)
Recent Studies (post-2010)
(campesterol)
Studies
(pyrroles)
Trials
(pyrroles)
Recent Studies (post-2010) (pyrroles)
4107516626,1292,81512,100

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (55.56)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gylling, H; Lindbohm, N; Miettinen, TA; Miettinen, TE; Rajaratnam, RA; Relas, H1
Barrett, PH; Chan, DC; O'Neill, FH; Thompson, GR; Watts, GF1
De Paepe, B; Laakso, J; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Mattila, KM; Päivä, H; Smet, J; Thelen, KM; Van Coster, R; von Bergmann, K1
Ho, SS; Pal, S1
Ai, M; Jones, PH; Matthan, NR; Otokozawa, S; Resteghini, NA; Schaefer, EJ; Stein, EA; van Himbergen, TM1
Ceglarek, U; Farmer, A; Holman, RR; Neil, HA; Paul, S; Thiery, J1
Covelli, D; Crisanti, F; De Vuono, S; Lupattelli, G; Mannarino, E; Pirro, M; Roscini, AR; Siepi, D1
Endo, T; Fukui, K; Himeno, H; Iwahashi, N; Iwasawa, Y; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okada, K; Sawada, R; Shigemasa, T; Shimizu, M; Shimizu, T; Uchino, K; Umemura, S; Wada, A1
Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM1

Trials

8 trial(s) available for campesterol and pyrroles

ArticleYear
Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.
    The Journal of laboratory and clinical medicine, 2003, Volume: 141, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; Cholestanol; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols; Squalene; Sterols

2003
Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003, Volume: 27, Issue:7

    Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, VLDL; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Phytosterols; Pyrroles

2003
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:1

    Topics: Adult; Age Factors; Aged; Atorvastatin; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Citrate (si)-Synthase; Dose-Response Relationship, Drug; Double-Blind Method; Electron Transport; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscles; Patient Selection; Phytosterols; Pyrroles; Sex Factors; Simvastatin; Sitosterols; Succinate Cytochrome c Oxidoreductase; Time Factors; Ubiquinone

2005
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.
    Journal of lipid research, 2009, Volume: 50, Issue:4

    Topics: Absorption; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol; Diabetes Complications; Female; Fluorobenzenes; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Phytosterols; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sterols; Sulfonamides

2009
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial.
    Atherosclerosis, 2010, Volume: 213, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Lanosterol; Phytosterols; Pyrroles; Triglycerides

2010
Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
    Life sciences, 2012, Jun-06, Volume: 90, Issue:21-22

    Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Lipids; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols

2012
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Atherosclerosis, 2012, Volume: 224, Issue:2

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Phytosterols; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Time Factors; Treatment Outcome

2012
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
    Life sciences, 2013, May-02, Volume: 92, Issue:14-16

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric

2013

Other Studies

1 other study(ies) available for campesterol and pyrroles

ArticleYear
Margarine phytosterols decrease the secretion of atherogenic lipoproteins from HepG2 liver and Caco2 intestinal cells.
    Atherosclerosis, 2005, Volume: 182, Issue:1

    Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Atherosclerosis; Atorvastatin; Caco-2 Cells; Carcinoma, Hepatocellular; Cholesterol; Drug Synergism; Enterocytes; Hepatocytes; Heptanoic Acids; Humans; Liver Neoplasms; Margarine; Phytosterols; Pyrroles; Sitosterols; Stigmasterol

2005